172 related articles for article (PubMed ID: 30081743)
1. Lactococcus lactis type III-A CRISPR-Cas system cleaves bacteriophage RNA.
Millen AM; Samson JE; Tremblay DM; Magadán AH; Rousseau GM; Moineau S; Romero DA
RNA Biol; 2019 Apr; 16(4):461-468. PubMed ID: 30081743
[TBL] [Abstract][Full Text] [Related]
2. Mobile CRISPR/Cas-mediated bacteriophage resistance in Lactococcus lactis.
Millen AM; Horvath P; Boyaval P; Romero DA
PLoS One; 2012; 7(12):e51663. PubMed ID: 23240053
[TBL] [Abstract][Full Text] [Related]
3. Genome Engineering of Virulent Lactococcal Phages Using CRISPR-Cas9.
Lemay ML; Tremblay DM; Moineau S
ACS Synth Biol; 2017 Jul; 6(7):1351-1358. PubMed ID: 28324650
[TBL] [Abstract][Full Text] [Related]
4. Cas13-induced cellular dormancy prevents the rise of CRISPR-resistant bacteriophage.
Meeske AJ; Nakandakari-Higa S; Marraffini LA
Nature; 2019 Jun; 570(7760):241-245. PubMed ID: 31142834
[TBL] [Abstract][Full Text] [Related]
5. Primed CRISPR-Cas Adaptation and Impaired Phage Adsorption in Streptococcus mutans.
Mosterd C; Moineau S
mSphere; 2021 May; 6(3):. PubMed ID: 34011685
[No Abstract] [Full Text] [Related]
6. A virulent phage infecting Lactococcus garvieae, with homology to Lactococcus lactis phages.
Eraclio G; Tremblay DM; Lacelle-Côté A; Labrie SJ; Fortina MG; Moineau S
Appl Environ Microbiol; 2015 Dec; 81(24):8358-65. PubMed ID: 26407890
[TBL] [Abstract][Full Text] [Related]
7. A jumbo phage that forms a nucleus-like structure evades CRISPR-Cas DNA targeting but is vulnerable to type III RNA-based immunity.
Malone LM; Warring SL; Jackson SA; Warnecke C; Gardner PP; Gumy LF; Fineran PC
Nat Microbiol; 2020 Jan; 5(1):48-55. PubMed ID: 31819217
[TBL] [Abstract][Full Text] [Related]
8. Spatiotemporal Control of Type III-A CRISPR-Cas Immunity: Coupling DNA Degradation with the Target RNA Recognition.
Kazlauskiene M; Tamulaitis G; Kostiuk G; Venclovas Č; Siksnys V
Mol Cell; 2016 Apr; 62(2):295-306. PubMed ID: 27105119
[TBL] [Abstract][Full Text] [Related]
9. Type III CRISPR-Cas systems can provide redundancy to counteract viral escape from type I systems.
Silas S; Lucas-Elio P; Jackson SA; Aroca-Crevillén A; Hansen LL; Fineran PC; Fire AZ; Sánchez-Amat A
Elife; 2017 Aug; 6():. PubMed ID: 28826484
[TBL] [Abstract][Full Text] [Related]
10. The CRISPR/Cas bacterial immune system cleaves bacteriophage and plasmid DNA.
Garneau JE; Dupuis MÈ; Villion M; Romero DA; Barrangou R; Boyaval P; Fremaux C; Horvath P; Magadán AH; Moineau S
Nature; 2010 Nov; 468(7320):67-71. PubMed ID: 21048762
[TBL] [Abstract][Full Text] [Related]
11. CRISPR-Cas systems exploit viral DNA injection to establish and maintain adaptive immunity.
Modell JW; Jiang W; Marraffini LA
Nature; 2017 Apr; 544(7648):101-104. PubMed ID: 28355179
[TBL] [Abstract][Full Text] [Related]
12. Cloning, expression, and sequence determination of a bacteriophage fragment encoding bacteriophage resistance in Lactococcus lactis.
Hill C; Miller LA; Klaenhammer TR
J Bacteriol; 1990 Nov; 172(11):6419-26. PubMed ID: 2121714
[TBL] [Abstract][Full Text] [Related]
13. Properties and genomic analysis of Lactococcus garvieae lysogenic bacteriophage PLgT-1, a new member of Siphoviridae, with homology to Lactococcus lactis phages.
Hoai TD; Nishiki I; Yoshida T
Virus Res; 2016 Aug; 222():13-23. PubMed ID: 27234995
[TBL] [Abstract][Full Text] [Related]
14. Efficient Genome Engineering of a Virulent Klebsiella Bacteriophage Using CRISPR-Cas9.
Shen J; Zhou J; Chen GQ; Xiu ZL
J Virol; 2018 Sep; 92(17):. PubMed ID: 29899105
[No Abstract] [Full Text] [Related]
15. Impact of Different Target Sequences on Type III CRISPR-Cas Immunity.
Maniv I; Jiang W; Bikard D; Marraffini LA
J Bacteriol; 2016 Jan; 198(6):941-50. PubMed ID: 26755632
[TBL] [Abstract][Full Text] [Related]
16. An anti-CRISPR from a virulent streptococcal phage inhibits Streptococcus pyogenes Cas9.
Hynes AP; Rousseau GM; Lemay ML; Horvath P; Romero DA; Fremaux C; Moineau S
Nat Microbiol; 2017 Oct; 2(10):1374-1380. PubMed ID: 28785032
[TBL] [Abstract][Full Text] [Related]
17. Molecular characterization of a second abortive phage resistance gene present in Lactococcus lactis subsp. lactis ME2.
Durmaz E; Higgins DL; Klaenhammer TR
J Bacteriol; 1992 Nov; 174(22):7463-9. PubMed ID: 1429469
[TBL] [Abstract][Full Text] [Related]
18. Investigating
Lemay ML; Otto A; Maaß S; Plate K; Becher D; Moineau S
Mol Cell Proteomics; 2019 Apr; 18(4):704-714. PubMed ID: 30679258
[TBL] [Abstract][Full Text] [Related]
19. Spacer Acquisition Rates Determine the Immunological Diversity of the Type II CRISPR-Cas Immune Response.
Heler R; Wright AV; Vucelja M; Doudna JA; Marraffini LA
Cell Host Microbe; 2019 Feb; 25(2):242-249.e3. PubMed ID: 30709780
[TBL] [Abstract][Full Text] [Related]
20. An origin of DNA replication from Lactococcus lactis bacteriophage c2.
Waterfield NR; Lubbers MW; Polzin KM; Le Page RW; Jarvis AW
Appl Environ Microbiol; 1996 Apr; 62(4):1452-3. PubMed ID: 8919811
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
